A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
NCT ID: NCT00721422
Last Updated: 2010-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
16 participants
INTERVENTIONAL
2008-08-31
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To investigate the safety and tolerability of a single dose of PD 0332334 in patients with impaired kidney function.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
NCT00730145
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function
NCT00596518
A Renal Impairment Study for PF-04965842
NCT03660241
Renal Impairment Study of PF-06700841
NCT04260464
PF-04634817 Renal Impairment Study
NCT01791855
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
On February 23rd 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1-Normal
PD 0332334
50 mg (two 25 mg capsules), single, oral dose
Group 2-Mild
PD 0332334
50 mg (two 25 mg capsules), single, oral dose
Group 3-Moderate
PD 0332334
50 mg (two 25 mg capsules), single, oral dose
Group 4-Severe
PD 0332334
50 mg (two 25 mg capsules), single, oral dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PD 0332334
50 mg (two 25 mg capsules), single, oral dose
PD 0332334
50 mg (two 25 mg capsules), single, oral dose
PD 0332334
50 mg (two 25 mg capsules), single, oral dose
PD 0332334
50 mg (two 25 mg capsules), single, oral dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. clinically significant or unstable medical disease other than kidney disease
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Cypress, California, United States
Pfizer Investigational Site
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5361023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.